Core Viewpoint - Coty Inc. is experiencing a transition phase following the departure of its CEO, leading to multiple downgrades from analysts and concerns about the company's future performance [1][2][3]. Group 1: Analyst Downgrades - Banco Santander downgraded Coty Inc. from Outperform to Neutral with a price target of $3.50, citing a prolonged transition phase due to the CEO change [1]. - Evercore ISI also downgraded Coty Inc. from Outperform to In Line, setting a price target of $7, and described the current moment as a "pivotal juncture" for the company [2]. - TD Cowen lowered its price target from $4.00 to $3.75 while maintaining a Hold rating, highlighting risks such as inventory reductions and a challenging environment in mass cosmetics [4]. Group 2: Company Performance and Challenges - The Consumer division of Coty Inc. accounts for approximately 15% of its profits but is associated with significant operational challenges and negative sentiment [3]. - Evercore ISI noted limited visibility on timing and catalysts for a potential value unlock, suggesting that the stock is currently undervalued but may remain so in the near term [3]. - The company is undergoing a strategic review of its Consumer division, which is critical for its future direction [2].

Core Viewpoint - Geron Corporation (NASDAQ:GERN) is undergoing a strategic restructuring plan aimed at long-term value creation and improved financial discipline, while maintaining a Neutral rating from H.C. Wainwright [1][3]. Group 1: Strategic Restructuring - The strategic restructuring plan will reduce Geron's workforce by approximately one-third, from around 260 employees [2]. - This restructuring is intended to streamline operations and focus on the commercial growth of RYTELO in the US, as well as explore international opportunities and progress on the Phase 3 IMpactMF trial [2][4]. Group 2: Financial Outlook - Geron expects its operating expenses in 2026 to be lower than those in 2025, with most cuts completed by the first quarter of 2026 [3]. - The company is projected to reach profitability in the second half of 2026 based on the anticipated reduction in operating expenses [3]. Group 3: Future Developments - An update on Geron's European commercialization strategy is expected in the first half of 2026 [4]. - Interim overall survival data from the IMpactMF trial is anticipated to be shared in the second half of 2026 [4].

Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1][2] - The investment group offers high-yield, dividend growth investment ideas, targeting dividend yields up to 10% [2] - The markets have shown significant gains at the start of 2026, with a notable interest in U.S. energy stocks like Chevron [2] Group 2 - The investment research covers various asset classes including REITs, ETFs, closed-end funds, preferreds, and dividend champions [2] - The service aims to help investors achieve dependable monthly income and portfolio diversification [2]

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except fixed income outside the U.S. posted positive returns. In addition, please check the fund’s top five holdings to know its best picks in 202 ...

Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - All asset classes except fixed income outside the U.S. posted positive returns during the quarter [1] - Inspire Medical Systems, Inc. (NYSE:INSP) experienced a one-month return of -32.57% and a 52-week loss of 56.01%, closing at $94.76 per share with a market capitalization of $2.802 billion on January 5, 2026 [2] Group 2 - Merus, a biopharma company, saw a 79% increase in shares due to positive clinical trial results, while Inspire Medical Systems faced a -38% loss in the same period, leading to an exit from the position by TimesSquare Capital [3] - Inspire Medical Systems reported revenue of $224.5 million for Q3 2025, reflecting a 10% increase from Q3 2024, but is not among the 30 most popular stocks among hedge funds, with 48 hedge fund portfolios holding its shares at the end of Q3 2025 [4] - The company is viewed as having potential, but certain AI stocks are considered to offer greater upside potential and less downside risk [4]

Core Insights - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - The fund's top five holdings were highlighted, indicating its best investment picks for 2025 [1] Company Analysis - NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biopharmaceutical firm focused on cholesterol inhibitors for cardiovascular diseases [3] - The stock of NewAmsterdam Pharma experienced a one-month decline of 3.79% but has gained 28.57% over the past 52 weeks, closing at $33.48 per share with a market capitalization of $3.796 billion as of January 5, 2026 [2] - NewAmsterdam's lead candidate, a CETP inhibitor, demonstrated significant LDL level reductions without adverse side effects, contributing to a 57% increase in its share price [3] Investment Sentiment - NewAmsterdam Pharma was held by 28 hedge fund portfolios at the end of Q3 2025, a decrease from 31 in the previous quarter, indicating a slight decline in popularity among hedge funds [4] - Despite the potential of NewAmsterdam as an investment, the company is viewed as having less upside compared to certain AI stocks, which are considered to carry less downside risk [4]

Group 1 - Colgate-Palmolive Company (NYSE:CL) is recognized as one of the "Dividend Kings," having increased its dividends for 63 consecutive years, which provides stability in an uncertain economy [3] - The company is focusing on everyday essentials, aiming to protect its market position through increased investment in research and innovation, enhanced marketing for core brands, and quicker responses to changing consumer preferences [3] - JPMorgan has raised its price target for Colgate-Palmolive to $88 from $87, maintaining an Overweight rating, with expectations of improved results as headwinds from 2025 are expected to ease [2] Group 2 - Colgate-Palmolive is managing higher raw material costs by implementing price increases, tighter revenue management, and improving operational efficiency [4] - The company has potential upside from its pet nutrition business, Hill's, which could benefit from the sustained demand for pet products following a surge in pet adoption during the pandemic [4] - The outlook for beverages, household, and personal care sectors remains challenging, but there is optimism for consumption and margins due to lower tariffs and favorable currency movements for multinational companies [2]

AI stocks could be hit if OpenAI can't sustain its growth—but Pivotal Research says these two technology companies would still be good bets. ...

Core Viewpoint - American Century Investments Small Cap Value Fund reported a strong performance in the third quarter of 2025, with equities rising and the US Federal Reserve reducing interest rates for the first time this year [1] Fund Performance - The investor class of the fund returned 4.69% in the third quarter, while the Russell 2000 Value Index returned 12.60% [1] Company Focus: Bath & Body Works, Inc. - Bath & Body Works, Inc. (NYSE:BBWI) was highlighted as a key investment, with a one-month return of 5.55% but a significant decline of 43.26% over the last 52 weeks [2] - As of January 2, 2026, Bath & Body Works, Inc. shares closed at $20.74, with a market capitalization of $4.276 billion [2] Investment Rationale - The fund initiated a position in Bath & Body Works, Inc. due to its high margins and potential for rapid growth, believing that the company's low valuation is temporary [3] - Strong free cash flows are expected to mitigate risks while waiting for strategic initiatives to take effect [3] Hedge Fund Interest - Bath & Body Works, Inc. was held by 49 hedge fund portfolios at the end of the third quarter, a decrease from 56 in the previous quarter [4] - While the company shows potential, the fund suggests that certain AI stocks may offer greater upside potential with less downside risk [4]

Group 1: Company Overview - American Water Works Company, Inc. (AWK) is the largest investor-owned water and wastewater company in the US, serving approximately 4 million customers across 14 states [5] Group 2: Recent Acquisition - New Jersey American Water, a subsidiary of American Water, has agreed to purchase the Hopewell Borough water system for $6.4 million, with the sale approved by 58% of Hopewell voters in a November 2025 referendum [3] - The Hopewell system serves over 880 customer connections, and American Water has been supplying a significant amount of Hopewell's water through a bulk water agreement for many years, ensuring a smooth transition [3] - The company plans to invest in the Hopewell system to repair outdated infrastructure, eliminate lead service lines, improve reliability, and maintain reasonable prices [3] Group 3: Analyst Ratings and Market Outlook - Barclays analyst Nicholas Campanella maintained an Underweight rating on AWK shares and reduced the price target from $134 to $122 as part of the utilities sector projection for 2026 [4] - Barclays has a strong outlook for the utilities industry, describing 2026 as a year of execution and defense due to increased spending commitments and positive adjustments to earnings expected to follow [4]